By Fineline Cube 
Beijing-based biotech InnoCare Pharma (HKG: 9969, SHA: 688428) announced that it has received clinical trial approval from the US Food and Drug Administration (FDA) for its mesutoclax (ICP-248) combined with azacitidine in myeloid malignancies, including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
Mesutoclax: A Targeted BCL2 Inhibitor
Mesutoclax is an innovative, orally available, and highly selective BCL2 inhibitor. BCL2 plays a key role in regulating the apoptosis pathway, and its abnormal expression is closely associated with the development and progression of various hematological malignancies. By selectively inhibiting BCL2, mesutoclax restores programmed cell death in tumor cells, thereby exerting its anti-tumor effects.
Clinical Significance
The FDA’s approval marks a significant step forward in the development of new therapies for myeloid malignancies. This combination therapy has the potential to offer new treatment options for patients with AML and MDS, diseases that continue to present significant challenges in clinical practice.-Fineline Info & Tech